Absent T Lymphocytes

Search Trials
Sunitinib in Treating Patients With Idiopathic Myelofibrosis
Status:
Terminated
Last Changed:
May 28, 2014
First Changed:
Oct 13, 2006
Disease(s):
Accelerated Phase Chronic Myelogenous Leukemia
Intervention(s):
sunitinib malate
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Status:
Completed
Last Changed:
May 30, 2017
First Changed:
Jul 11, 2005
Disease(s):
Acute Undifferentiated Leukemia
Intervention(s):
alemtuzumabtotal-body irradiationfludarabine phosphatecyclosporinemycophenolate mofetilallogeneic hematopoietic stem cell transplantationperipheral blood stem cell transplantationgraft versus host disease prophylaxis/therapylaboratory biomarker analysis
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
Status:
Completed
Last Changed:
Jul 19, 2018
First Changed:
May 12, 2009
Disease(s):
Acute Undifferentiated Leukemia
Intervention(s):
Cytology Specimen Collection Procedure
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Status:
Completed
Last Changed:
Oct 30, 2019
First Changed:
Mar 4, 2005
Disease(s):
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Intervention(s):
Fludarabine PhosphateTotal-Body IrradiationPeripheral Blood Stem Cell TransplantationAllogeneic Hematopoietic Stem Cell TransplantationTacrolimusMycophenolate MofetilSirolimus
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer
Status:
Completed
Last Changed:
Apr 2, 2014
First Changed:
Nov 3, 2010
Disease(s):
Accelerated Phase Chronic Myelogenous Leukemia
Intervention(s):
paliferminflow cytometrylaboratory biomarker analysispharmacological study

Connect. Empower. Inspire.